Chronic Kidney Disease Does Not Influence Response to Terlipressin in Hepatorenal Syndrome-Acute Kidney Injury

What Was Tested

This observational study looks at Terlipressin.

This multicenter, retrospective, observational study aimed to investigate treatment response of terlipressin (+ albumin) in patients with HRS-AKI and CKD compared with patients without CKD.

Who Took Part

According to the abstract, 395 patients were involved.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

A total of 395 patients who received albumin/terlipressin were retrospectively analyzed and stratified according to presence of CKD at baseline.

The primary endpoint was a complete response to terlipressin treatment.

How the Study Was Run

The researchers set it up as a multicenter study.

More than one site took part, so the patients came from several places.

Secondary endpoints included adverse events, need for renal replacement therapy and 12-month liver transplantation-free survival.

What Was Measured

PubMed files the paper under topics including Terlipressin, Hepatorenal Syndrome, Renal Insufficiency, Chronic, Lypressin, Vasoconstrictor Agents, Acute Kidney Injury and Survival Analysis.

Author keywords: Chronic Kidney Disease, Cirrhosis and Portal Hypertension.

What This Means in Plain Language

The paper is a multicenter study of Terlipressin in 395 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2026 (Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association), a journal based in United States.

More context: the Terlipressin compound page, all human trials.